A multicenter, Phase 1b, double-blind, placebo-controlled study to evaluate the safety and tolerability, and the efficacy of si-544 in adults with psoriasis vulgaris or psoriatic arthritis
Phase 1
Recruiting
- Conditions
- psoriasis vulgaris, psoriatic arthritisMedDRA version: 20.0Level: LLTClassification code: 10050576Term: Psoriasis vulgaris Class: 10040785MedDRA version: 21.0Level: LLTClassification code: 10037160Term: Psoriatic arthritis Class: 10028395Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- CTIS2023-507393-40-00
- Lead Sponsor
- selectION Therapeutics GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method